HuGE Literature Finder
Records
1
-
6
TYMS 3'-UTR Polymorphism: A Novel Association with FOLFIRINOX-Induced Neurotoxicity in Pancreatic Cancer Patients. Pharmaceutics 2021 Dec 14 (1): . Emelyanova Marina, Pokataev Ilya, Shashkov Igor, Kopantseva Elena, Lyadov Vladimir, Heydarov Rustam, Mikhailovich Vladim |
Clinical Value of Pharmacogenomic Testing in a Patient Receiving FOLFIRINOX for Pancreatic Adenocarcinoma. Frontiers in pharmacology 2018 9 1309. Velez-Velez Lisa M, Hughes Caren L, Kasi Pashtoon Murta |
Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan-related toxicities in patients with lung cancer. Thoracic cancer 2017 Oct . Fukuda Minoru, Okumura Manabu, Iwakiri Tomomi, Arimori Kazuhiko, Honda Takuya, Kobayashi Kazuma, Senju Hiroaki, Takemoto Shinnosuke, Ikeda Takaya, Yamaguchi Hiroyuki, Nakatomi Katsumi, Matsuo Nobuko, Mukae Hiroshi, Ashizawa Kazu |
Variations of chromosome 2 gene expressions among patients with lung cancer or non-cancer. Cell biology and toxicology 2016 Jun . Bao Lianmin, Zhang Yong, Wang Jian, Wang Haiyun, Dong Nian, Su Xiaoqiong, Xu Menglin, Wang Xiangdo |
A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. Cancer chemotherapy and pharmacology 2013 Jun 71 (6): 1609-17. Kim Kyu-pyo, Kim Ho-Sook, Sym Sun Jin, Bae Kyun Seop, Hong Yong Sang, Chang Heung-Moon, Lee Jae Lyun, Kang Yoon-Koo, Lee Jung Shin, Shin Jae-Gook, Kim Tae W |
High enzyme activity UGT1A1 or low activity UGT1A8 and UGT2B4 genotypes increase esophageal cancer risk. International journal of oncology 2012 Jun 40 (6): 1789-96. Dura Polat, Salomon Jody, Te Morsche Rene H M, Roelofs Hennie M J, Kristinsson Jon O, Wobbes Theo, Witteman Ben J M, Tan Adriaan C I T L, Drenth Joost P H, Peters Wilbert H |
- Page last reviewed:Feb 1, 2023
- Page last updated:Feb 03, 2023
- Content source: